Elotuzumab: the first available immunotherapeutic arrow against relapsed-refractory Multiple Myeloma. Eur J Oncol [Internet]. 2017 Nov. 17 [cited 2024 Jul. 18];22(2):65-70. Available from: https://mattioli1885journals.com/index.php/EJOEH/article/view/6857